

**Indian Hospital Industry** 

Industry to post robust performance in FY2023

**DECEMBER 2022** 



### Highlight



Revenue growth to remain healthy; supported by strong occupancy and higher ARPOB levels.

Profit margins and debt coverage indicators to remain strong in FY2023.

ICRA's sample set to add ~1,100-1,200 beds in FY2023.



• ICRA's sample set<sup>1</sup> of hospitals witnessed healthy revenue growth of 12% and operating profit margin (OPM) of 21.8% in H1 FY2023 on the back of improvement in both occupancy and ARPOB. Q2 FY2023 witnessed the highest-ever quarterly OPM of 22.8%, in the last several years, backed by improved occupancy, better specialty mix and turnaround in operations of many of the new centres for some hospitals.



Aggregate occupancy for ICRA's sample for FY2023 is estimated at 62-64%. On a YoY basis, given the large base in FY2022, this translates to revenue growth of 15-17%. OPM for the sample set is expected to remain healthy at over 20% in FY2023.



■ The ARPOB of the sample set is expected to witness healthy growth of 8-10% in FY2023 on the back of price increases taken by companies to offset high input cost inflation, relatively higher elective surgeries, improving payor mix and faster throughput in discharges.



■ Revenue growth for the sample set is expected to moderate to ~4-6% in FY2024, given the expectations of moderate ARPOB growth. That said, continued benefits from cost optimisation measures implemented during the pandemic and improvement in margin-accretive medical tourism will support the OPM in FY2024.



■ Credit metrics for companies in the sector will remain strong in the medium-term. The interest coverage ratio is expected to be within 7-7.5x in FY2023 and FY2024, while the net debt/OPBDITA is expected to be in the range of ~0.7-0.8x as on March 31, 2023, and March 31, 2024, on the back of strong accruals, despite ongoing capex.



The outlook for the industry remains Stable as the credit profile of the companies in the ICRA sample is expected to remain healthy, given the rising incidence of non-communicable lifestyle diseases, growing per capita spend on healthcare and awareness levels, increasing penetration of health insurance and revival in medical tourism volumes.

<sup>&</sup>lt;sup>1</sup> ICRA's sample of companies includes hospital business of seven listed companies

## Agenda













•		Shamsher Dewan	Kinjal Shah	Mythri Macherla	Seetha Pillai
		Group Head	Co-Group Head	Sector Head	Senior Analyst
_	ê	shamsherd@icraindia.com	kinjal.shah@icraindia.com	mythri.macherla@icraindia.com	seetha.pillai@icraindia.com
_		0124 – 4545 328	022 - 6114 3442	080 – 4332 6407	080 – 4332 6411

















# **ICRA Business Development/Media Contact Details**

	L. Shivakumar	Jayanta Chatterjee	Naznin Prodhani
	Executive Vice-President	Executive Vice-President	Head Media & Communications
<u></u>	shivakumar@icraindia.com	jayantac@icraindia.com	communications@icraindia.com
C	022- 6114 3406	080 – 4332 6401	0124 – 4545 860



















#### © Copyright, 2022 ICRA Limited. All Rights Reserved.

All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



# **Thank You!**

